Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.

MLA

Jackson, Graham H., et al. “Lenalidomide before and after Autologous Stem Cell Transplantation for Transplant-Eligible Patients of All Ages in the Randomized, Phase III, Myeloma XI Trial.” Haematologica, vol. 106, no. 7, July 2021, pp. 1957–67. EBSCOhost, https://doi.org/10.3324/haematol.2020.247130.

APA

Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M., Williams, C. D., Karunanithi, K., Lindsay, J., Allotey, D., Shafeek, S., Jenner, M. W., Cook, G., Russell, N. H., Kaiser, M. F., … Clinical Studies Group, U. N. H. O. (2021). Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, 106(7), 1957–1967. https://doi.org/10.3324/haematol.2020.247130

Chicago

Jackson, Graham H, Faith E Davies, Charlotte Pawlyn, David A Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, et al. 2021. “Lenalidomide before and after Autologous Stem Cell Transplantation for Transplant-Eligible Patients of All Ages in the Randomized, Phase III, Myeloma XI Trial.” Haematologica 106 (7): 1957–67. doi:10.3324/haematol.2020.247130.